Wuxi Apptec has rebounded 17% from 106 yuan, and a breakthrough above 129 yuan is required to open up the upward space.

Wuxi Apptec (02359.HK) has consolidated above 120 yuan recently with a strong trend. As of April 8, 2026, Wuxi Apptec closed at 128.6 yuan, up 3.21%, with a trading volume of 443 million yuan. The stock price has rebounded about 17% from the low point near 106 yuan in late March. The market is watching whether it can break through the resistance level at 129 yuan.

In terms of peers, Wuxi Bio (02269.HK) closed at 35.62 yuan on April 8, up 1.25%; while ClinChoice (03759.HK) closed at 20.92 yuan, up 1.36%. The CXO sector's overall sentiment has warmed up, with market expectations for the industry outlook improving.

Technical Analysis

From the chart movement, Wuxi Apptec’s stock price gradually recovered after hitting a low of 106.3 yuan on March 23, and since April, it has successively stabilized above the 115 yuan and 120 yuan levels. According to technical data as of April 8, Wuxi Apptec's first support level is around 115.3 yuan, which serves as the initial support zone following the recent breakout; the more critical second support level is at 107.2 yuan, equivalent to the adjustment low in late March. In terms of resistance, the first resistance is at 129.2 yuan, and if it breaks through, the next target will be 142 yuan, i.e., the high area in February.

Regarding technical indicators, the overall signal shows 'Strong Sell,' with a total of 12 sell signals. RSI stands at 67, nearing the overbought edge. Multiple oscillation indicators show neutral signals, but the Williams %R and Stochastic Oscillators have both issued sell signals, and the ADX indicator also indicates selling pressure. However, trend-following indicators like the Bull/Bear Power Indicator, Ichimoku Cloud, MACD, and Bollinger Bands all suggest buying opportunities, reflecting that the medium-term uptrend remains intact, though short-term overbought pressures are increasing. Overall, the current technical signals present a pattern of 'short-term strength but potential for pullback.' In the short term, the stock is expected to trade within the range of 115.3 yuan to 129.2 yuan, and only a breakout above 129.2 yuan can open up further upside potential.

Market News Integration

In terms of news, positive factors for Wuxi Apptec have recently emerged. On April 7, the company announced that its subsidiary, Wuxi Apptec Biomedical Technology Co., Ltd., had received approval from the pharmaceutical regulatory authority to conduct a clinical trial for a new bispecific antibody drug for the treatment of advanced solid tumors, further enriching its R&D pipeline. Morgan Stanley issued a report maintaining an 'Overweight' rating for Wuxi Apptec with a target price of 150 yuan, citing the company’s integrated platform advantages and increased global market share as support for long-term growth. Citi also reiterated a 'Buy' rating with a target price of 148 yuan. In terms of capital flow, northbound capital net bought approximately 120 million yuan worth of Wuxi Apptec A-shares on April 8, while Stock Connect recorded continuous inflows for three days, accumulating about 250 million yuan.

Review of Warrant Products

Regarding the review of warrant products, the two Wuxi Apptec call warrants mentioned on March 31, 2026, performed significantly in the following two trading days (up to April 2). During this period, the underlying stock, Wuxi Apptec, rose by 6.30%, and the related call warrants fully demonstrated the leverage effect: the Merrill Lynch call warrant (19210) $MS-WXAT@EC2606A.C (19210.HK)$ showed the most outstanding performance, rising by 42%, while the Societe Generale call warrant (23924) $SG-WXAT@EC2606B.C (23924.HK)$ also rose by 30%. The data shows that the increase in the call warrants was much higher than that of the underlying stock, which is a core characteristic of leveraged products—investors use less capital to capture movements in the underlying stock, thereby amplifying returns.

Recommendation and Comparison of Warrant Products

With the current Wuxi Apptec stock price at 124.6 yuan, along with support levels at 115.3 yuan and 107.2 yuan, and resistance levels at 129.2 yuan and 142 yuan, investors can choose suitable products based on their own views. Below is a brief comparison of four call warrants:

- Huatai call warrant (23591) $HU-WXAT@EC2606A.C (23591.HK)$ : Exercise price of 143 yuan, out-of-the-money by only 10.94%, premium of 16.8% (lowest), effective leverage of 6.56 times, high safety margin, best cost-performance ratio.

- Societe Generale call warrant (19704) $SG-WXAT@EC2606A.C (19704.HK)$ : Exercise price of 163.69 yuan, out-of-the-money by 27%, effective leverage of 7.17 times (highest), street ratio of 0.86%, suitable for aggressive short-term investors looking for a breakout.

- Macquarie call warrant (22606) $MB-WXAT@EC2606A.C (22606.HK)$ : Strike price 158.36 yuan, out-of-the-money by 22.85%, effective leverage 5.5x, premium 28.71%, strong value tracking advantage, suitable for medium-term positioning.

- JPMorgan call warrant (20161) $JP-WXAT@EC2606A.C (20161.HK)$ : Strike price 163.33 yuan, out-of-the-money by 26.71%, effective leverage 6.17x, implied volatility 72.78% relatively high, strong trading characteristics.

Two highlighted bullish products:

- Huatai call warrant (23591): Smaller out-of-the-money range, lowest premium, high margin of safety, suitable for conservative investors.

- Societe Generale call warrant (19704): Highest leverage, very low street inventory, suitable for aggressive investors seeking short-term breakout opportunities.

For bearish strategies, there are currently no Wuxi Apptec-related put warrants or bear contracts available in the market; investors considering a bearish view may look to index derivatives or wait and see.

Overall, Wuxi Apptec’s share price is currently in a consolidation phase after rebounding, with repeated contention around the 124-yuan level, while resistance at 129.2 yuan will determine the short-term direction. Fundamentally, positive factors such as new drug clinical approvals and institutional optimism provide support, but the RSI technical indicator at 67 indicates potential short-term overbought pressure that needs attention. Investors should strictly control risk when deploying positions, selecting appropriate call warrants based on key support levels of 115.3 yuan and 107.2 yuan, and resistance levels of 129.2 yuan and 142 yuan, while also monitoring the impact of out-of-the-money ranges on product performance.

Interactive Q&A:

Dear readers, do you think Wuxi Apptec (02359) can break through the 129.2-yuan resistance in the short term?

A) Yes, benefiting from progress in new drugs, further testing towards 142 yuan

B) No, the resistance at 129.2 yuan is heavy, need to retest the support level at 115.3 yuan

C) Repeated fluctuations in the range between 120 yuan and 129.2 yuan

Feel free to share your views in the comment section!

Reminder: This article does not constitute any investment advice.

This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should combine other data and should not solely rely on this article to make trading decisions. Please note that past performance is not indicative of future results. Follow Jenny's insights on Hong Kong stock warrants for more professional analysis.

$Hang Seng Index (800000.HK)$$Hang Seng TECH Index (800700.HK)$$Hang Seng China Enterprises Index (800100.HK)$

#Wuxi Apptec# #Hong Kong stocks# #Technical analysis# #Support and resistance levels# #Derivatives# #Call warrants# #CXO sector# #New drug approval# #Hong Kong stock derivatives Jenny#

72K Views